Liberty Amador Barry, MD
Family Medicine · Centennial, CONPI 1730100066
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $26,879 of the $30,270 with a category attached, or 88.8%. It is spread thinly across 60 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $7,673 and has fallen 57.3% since, to $3,277 in 2025. Among family medicine clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,320 payments — averaging $22.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$7K
- AbbVie$4K
- Amgen$4K
- Novo Nordisk$2K
- Pfizer$1K
- Lilly USA, LLC$1K
- plus $10K from 54 others
What the payments were for
- Consulting fees$1,9206%
- Speaking & faculty fees$1,1504%
- Food & beverage$26,87989%
- Education$3211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,270 in reported general payments places this provider in the 95th percentile of 2,079 family medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 84 | $133,554 |
| FarxigaDapagliflozin Propanediol | 40 | $58,876 |
| EliquisApixaban | 43 | $46,732 |
| Teriparatide | 19 | $43,239 |
| MyrbetriqMirabegron | 41 | $38,832 |
| JardianceEmpagliflozin | 31 | $36,356 |
| Repatha SureclickEvolocumab | 21 | $26,223 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $19,860 |
| XareltoRivaroxaban | 17 | $17,715 |
| TrulicityDulaglutide | 11 | $10,810 |
| Xigduo XrDapaglifloz Propaned/Metformin | 14 | $10,360 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $5,811 |
| LexaproEscitalopram Oxalate | 12 | $5,356 |
| DayvigoLemborexant | 16 | $5,344 |
| SynthroidLevothyroxine Sodium | 69 | $4,592 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $2,455 | $133,55484 claims |
| AstraZenecaFarxiga, Symbicort | $7,121 | $64,68760 claims |
| PfizerEliquis, Dilantin | $1,306 | $48,98654 claims |
| Astellas Pharma US IncMyrbetriq | $593 | $38,83241 claims |
| Boehringer IngelheimJardiance | $791 | $36,35631 claims |
| GSKTrelegy Ellipta | $498 | $19,86012 claims |
| Johnson & JohnsonXarelto | $1,172 | $17,71517 claims |
| Lilly USA, LLCTrulicity | $1,253 | $10,81011 claims |
| AbbVieLexapro, Synthroid | $4,397 | $9,94881 claims |
| Eisai Inc.Dayvigo | $521 | $5,34416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Centennial
- Jennifer ArnoldCentennial$12K
- Ethan LazarusDenver$688K
- Michael de NardisLarkspur$335K
- Matthew YoungColorado Springs$270K
- Mark DeutchmanDenver$258K
- Kari UusinarkausWoodland Park$254K
- Michael MeekerUsaf Academy$174K
- Carolynn Francavilla BrownLakewood$174K
- Lawrence AndrewsColorado Springs$102K
- Gregory MaederWestminster$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.